releases: https://davids.house.gov/media/press-releases/following-prescription-drug-roundtable-rep-davids-supports-bills-lower
Data license: MIT · Data source: dwillis/congress-press
This data as json
| url | title | date | year | month | party | chamber | state | member_name | bioguide_id | domain | scraper | source | date_source | text | has_text | collected_at | updated_at |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| https://davids.house.gov/media/press-releases/following-prescription-drug-roundtable-rep-davids-supports-bills-lower | Following Prescription Drug Roundtable, Rep. Davids Supports Bills to Lower Prescription Drug Costs | 2019-04-24 | 2019 | 2019-04 | Democrat | House | KS | Sharice Davids | D000629 | davids.house.gov | legacy | Following apublicroundtable on rising prescription drugs costs last week, Rep. ShariceDavidsannounced today she is supporting two bills to lower the price of prescription drugs and increase transparency in drug pricing to help Kansas families. During our roundtable discussion, I heard from so many families in the Third District who are struggling to pay for the prescription drugs that they or their loved ones depend on to survive. These bills would help drive down prescription drugs prices andincreasetransparency and oversight, giving our families some much-needed relief,saidDavids. Among the topics covered during the roundtable were getting generic drugs to market fastertoprovide affordable alternatives to brand name prescription drugs,andincreasingdrug pricing transparency to stop drug companies from unjustlyraising prices.The legislationDavidsis supporting addressesbothissues. It's refreshing to see someone in Washington start a serious dialog on healthcare. I've been in healthcare my entire careerand fought my ownhealthcarebattlesso I've seen firsthand some of the failures in the system. The problems facing health care are systemic. A band-aid approach just won't fix it,said Matthew Mellor, a cancer survivor and panelist on the roundtable. The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Actpromotescompetition in the market for drugs and biological products byspeeding theentry of lower-cost generic and biosimilar versions of those drugs and biological products. The Prescription Drug Price Transparency Actcreatesadditional transparency requirements for pharmacy benefit managers (PBMs) underthe Medicare prescription drug program and Medicare Advantage programto further transparency of payment methodologies to pharmacies. Theskyrocketingcostof prescription drugsisconsistentlyat the top of list when people tell me about their health care concerns.That's why Ibrought together a group of individuals that understand our prescription drug system to discuss this issue and look for solutions,like these pieces of legislation.Ilook forward to continuingthese important conversationsabout our health care system with the people of the Third District,saidDavids. | 1 | 2026-03-30T12:14:52Z | 2026-03-30T12:14:52Z |